<p>2025 年 11 月 13 日- 上午 08:39</p>
<p>马里兰州贝塞斯达 --（商业资讯）-- <strong>Global Medical REIT Inc. (NYSE:GMRE)</strong>（“公司”）今天宣布开始进行其系列 B 累积可赎回优先股的承销公开发行，面值每股 0.001 美元（“系列 B 优先股”），具体情况取决于市场和其他条件。公司预计将授予承销商 30 天的选择权，以购买额外的系列 B 优先股以覆盖超额配售（如有）。公司打算将此次发行的净收益用于一般企业用途，包括资助新收购和偿还债务，包括公司信贷额度下的未偿还金额。</p>
<p>公司打算申请在纽约证券交易所上市系列 B 优先股，股票代码为 “GMRE-PrB”。</p>
<p>Raymond James、BMO 资本市场、Stifel 和 Baird 担任此次发行的账簿管理人。</p>
<p>此次发行是根据公司已修订的货架注册声明进行的，该声明于 2024 年 4 月 4 日获得美国证券交易委员会（“SEC”）的有效声明。与此次发行相关的初步招股说明书补充及附带招股说明书将提交给 SEC，并可从 SEC 网站 www.sec.gov 获取，或通过以下方式联系：Raymond James &amp; Associates, Inc.，注意：股权承销部，880 Carillon Parkway, St. Petersburg, Florida 33716，电话：(800) 248-8863，或通过电子邮件联系：prospectus@raymondjames.com；BMO Capital Markets Corp.，注意：股权承销部，151 W 42nd Street, 32nd Floor, New York, NY 10036，或通过电子邮件联系：bmoprospectus@bmo.com；Stifel, Nicolaus &amp; Company, Incorporated，注意：承销部，1201 Wills Street, Suite 600, Baltimore, MD 21231，或通过电子邮件联系：syndprospectus@stifel.com；Robert W. Baird &amp; Co. Incorporated，注意：承销部，777 E. Wisconsin Avenue, Milwaukee, WI 53202，电话：800-792-2473，电子邮件：syndicate@rwbaird.com。</p>
<p>本新闻稿不构成出售要约或购买要约的招揽，也不应在任何州进行这些股份或其他证券的销售，若该等要约、招揽或销售在任何州违反证券法，则在注册或资格之前。</p>
<p><strong>关于 Global Medical REIT Inc.</strong></p>
<p>Global Medical REIT Inc.是一家净租赁医疗房地产投资信托，收购医疗设施并将这些设施租赁给医生集团及区域和国家医疗系统。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中包含的某些声明可能被视为 1995 年《私人证券诉讼改革法》意义上的 “前瞻性声明”，公司意图使任何此类声明受到该法案所创建的安全港保护。这些前瞻性声明通过使用 “预期”、“相信”、“可能”、“估计”、“期望”、“打算”、“可能”、“应该”、“计划”、“预测”、“项目”、“将”、“继续” 等术语和短语以及对未来结果的假设和预测的引用来识别。本新闻稿中的前瞻性声明示例包括关于系列 B 优先股拟议发行、预计的发行收益用途以及系列 B 优先股在纽约证券交易所上市的声明。这些前瞻性声明基于我们当前的预期、估计和假设，并受到某些风险和不确定性的影响。尽管公司相信其前瞻性声明中反映的预期、估计和假设是合理的，但实际结果可能与公司前瞻性声明中预测或假设的结果有重大差异。有关公司及其业务的更多信息，包括可能对其财务结果产生重大不利影响的其他因素，包括但不限于在公司 10-K 表格年报的第一部分第 1A 项 - 风险因素中描述的风险。您被警告不要对前瞻性声明过度依赖。公司不打算，也不承担更新任何前瞻性声明的义务。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNzMyMTdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNzMyMTdyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251113273217/en/</p>
<p><strong>投资者关系：</strong></p>
<p>电子邮件：Investors@globalmedicalreit.com</p>
<p>电话：202.524.6869</p>
<p>来源：Global Medical REIT Inc.</p>

GMRE

<p>全球医疗房地产投资信托公司（Global Medical REIT Inc.）宣布将进行一项系列 B 优先股的公开发行，具体情况将视市场条件而定。此次发行包括承销商在 30 天内购买额外股份的选择权。所得款项将用于公司用途，包括收购和债务偿还。该股票将在纽约证券交易所上市，代码为 “GMRE-PrB”。Raymond James、BMO Capital Markets、Stifel 和 Baird 正在管理此次发行。此次发行是在公司已获美国证券交易委员会（SEC）批准的货架注册声明下进行的</p>

<p>11/13/2025 - 08:39 AM</p>
<div class="lb-trans"><p>2025 年 11 月 13 日- 上午 08:39</p>
</div><p>BETHESDA, Md.--(BUSINESS WIRE)-- <strong>Global Medical REIT Inc. (NYSE:GMRE)</strong>(the “Company”) today announced the commencement of an underwritten public offering of shares of its Series B Cumulative Redeemable Preferred Stock, $0.001 par value per share (“Series B Preferred Stock”), subject to market and other conditions. The Company expects to grant the underwriters a 30-day option to purchase additional shares of Series B Preferred Stock to cover over-allotments, if any. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include funding new acquisitions and repaying indebtedness, including amounts outstanding under the Company’s credit facility.</p>
<div class="lb-trans"><p>马里兰州贝塞斯达 --（商业资讯）-- <strong>Global Medical REIT Inc. (NYSE:GMRE)</strong>（“公司”）今天宣布开始进行其系列 B 累积可赎回优先股的承销公开发行，面值每股 0.001 美元（“系列 B 优先股”），具体情况取决于市场和其他条件。公司预计将授予承销商 30 天的选择权，以购买额外的系列 B 优先股以覆盖超额配售（如有）。公司打算将此次发行的净收益用于一般企业用途，包括资助新收购和偿还债务，包括公司信贷额度下的未偿还金额。</p>
</div><p>The Company intends to apply to list the Series B Preferred Stock on the New York Stock Exchange under the ticker symbol “GMRE-PrB.”</p>
<div class="lb-trans"><p>公司打算申请在纽约证券交易所上市系列 B 优先股，股票代码为 “GMRE-PrB”。</p>
</div><p>Raymond James, BMO Capital Markets, Stifel and Baird are serving as the book-running managers for the offering.</p>
<div class="lb-trans"><p>Raymond James、BMO 资本市场、Stifel 和 Baird 担任此次发行的账簿管理人。</p>
</div><p>The offering is being made pursuant to the Company’s shelf registration statement, as amended, which was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on April 4, 2024. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, which will be filed with the SEC and may be obtained from the SEC’s website at www.sec.gov or by contacting: Raymond James &amp; Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at prospectus@raymondjames.com; BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at bmoprospectus@bmo.com; Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate Department, 1201 Wills Street, Suite 600, Baltimore, MD 21231, or by email at syndprospectus@stifel.com; and Robert W. Baird &amp; Co. Incorporated, Attention: Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, WI 53202, telephone: 800-792-2473, email: syndicate@rwbaird.com.</p>
<div class="lb-trans"><p>此次发行是根据公司已修订的货架注册声明进行的，该声明于 2024 年 4 月 4 日获得美国证券交易委员会（“SEC”）的有效声明。与此次发行相关的初步招股说明书补充及附带招股说明书将提交给 SEC，并可从 SEC 网站 www.sec.gov 获取，或通过以下方式联系：Raymond James &amp; Associates, Inc.，注意：股权承销部，880 Carillon Parkway, St. Petersburg, Florida 33716，电话：(800) 248-8863，或通过电子邮件联系：prospectus@raymondjames.com；BMO Capital Markets Corp.，注意：股权承销部，151 W 42nd Street, 32nd Floor, New York, NY 10036，或通过电子邮件联系：bmoprospectus@bmo.com；Stifel, Nicolaus &amp; Company, Incorporated，注意：承销部，1201 Wills Street, Suite 600, Baltimore, MD 21231，或通过电子邮件联系：syndprospectus@stifel.com；Robert W. Baird &amp; Co. Incorporated，注意：承销部，777 E. Wisconsin Avenue, Milwaukee, WI 53202，电话：800-792-2473，电子邮件：syndicate@rwbaird.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these shares or any other securities in any state in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any state.</p>
<div class="lb-trans"><p>本新闻稿不构成出售要约或购买要约的招揽，也不应在任何州进行这些股份或其他证券的销售，若该等要约、招揽或销售在任何州违反证券法，则在注册或资格之前。</p>
</div><p><strong>About Global Medical REIT Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Global Medical REIT Inc.</strong></p>
</div><p>Global Medical REIT Inc. is a net-lease medical REIT that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems.</p>
<div class="lb-trans"><p>Global Medical REIT Inc.是一家净租赁医疗房地产投资信托，收购医疗设施并将这些设施租赁给医生集团及区域和国家医疗系统。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements contained in this press release may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company’s intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;could,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;should,&#34; &#34;plan,&#34; &#34;predict,&#34; &#34;project,&#34; &#34;will,&#34; &#34;continue&#34; and other similar terms and phrases, including references to assumptions and forecasts of future results. Examples of forward-looking statements in this press release include statements regarding the proposed offering of the Series B Preferred Stock, the expected use of proceeds from the offering and the listing of shares of Series B Preferred Stock on the New York Stock Exchange. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company’s forward-looking statements. Additional information concerning the Company and its business, including additional factors that could materially and adversely affect its financial results, include, without limitation, the risks described under Part I, Item 1A - Risk Factors, in the Company’s Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and in its other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement.</p>
<div class="lb-trans"><p>本新闻稿中包含的某些声明可能被视为 1995 年《私人证券诉讼改革法》意义上的 “前瞻性声明”，公司意图使任何此类声明受到该法案所创建的安全港保护。这些前瞻性声明通过使用 “预期”、“相信”、“可能”、“估计”、“期望”、“打算”、“可能”、“应该”、“计划”、“预测”、“项目”、“将”、“继续” 等术语和短语以及对未来结果的假设和预测的引用来识别。本新闻稿中的前瞻性声明示例包括关于系列 B 优先股拟议发行、预计的发行收益用途以及系列 B 优先股在纽约证券交易所上市的声明。这些前瞻性声明基于我们当前的预期、估计和假设，并受到某些风险和不确定性的影响。尽管公司相信其前瞻性声明中反映的预期、估计和假设是合理的，但实际结果可能与公司前瞻性声明中预测或假设的结果有重大差异。有关公司及其业务的更多信息，包括可能对其财务结果产生重大不利影响的其他因素，包括但不限于在公司 10-K 表格年报的第一部分第 1A 项 - 风险因素中描述的风险。您被警告不要对前瞻性声明过度依赖。公司不打算，也不承担更新任何前瞻性声明的义务。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNzMyMTdyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251113273217r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251113273217/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251113273217/en/</p>
</div><p><strong>Investor Relations:</strong></p>
<div class="lb-trans"><p><strong>投资者关系：</strong></p>
</div><p>Email: Investors@globalmedicalreit.com</p>
<div class="lb-trans"><p>电子邮件：Investors@globalmedicalreit.com</p>
</div><p>Phone: 202.524.6869</p>
<div class="lb-trans"><p>电话：202.524.6869</p>
</div><p>Source: Global Medical REIT Inc.</p>
<div class="lb-trans"><p>来源：Global Medical REIT Inc.</p>
</div>

Global Medical REIT Inc. 宣布计划公开发行 B 系列优先股 | GMRE 股票新闻